| Literature DB >> 20097169 |
Shaobo Jin1, Karin Agerman, Karin Kolmodin, Elin Gustafsson, Camilla Dahlqvist, Anders Jureus, Gang Liu, Johanna Fälting, Stefan Berg, Johan Lundkvist, Urban Lendahl.
Abstract
beta-Secretase (BACE) is an aspartyl protease, which proteolytically processes amyloid precursor protein, making BACE an interesting pharmacological target in Alzheimer's disease. To study the enzymatic function of BACE, we mutated either of the two aspartic acid residues in the active site of BACE. This rendered BACE functionally inactive without affecting the degree of glycosylation or endosomal localization. In contrast, substituting both active site aspartic acid residues produced a functionally inactive, endoplasmic reticulum-retained and partially glycosylated BACE. Interestingly, co-expression of the two single active site mutants partially restored beta-site cleavage of amyloid precursor protein, and the restored activity was inhibited with similar dose-dependency and potency as wildtype BACE by a small molecule inhibitor raised against BACE. In sum, our data suggest that two different active site mutants can complement each other in a partially functional BACE dimer and mediate APP processing. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20097169 DOI: 10.1016/j.bbrc.2010.01.064
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575